Faculty of Science and Engineering

School of Biomedical Sciences

2021-03

Galleria mellonella larvae exhibit a weight-dependent lethal median dose when infected with methicillin-resistant Staphylococcus aureus

Hesketh-Best, PJ

http://hdl.handle.net/10026.1/16889

10.1093/femspd/ftab003 Pathogens and Disease Oxford University Press (OUP)

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

1 Galleria mellonella larvae exhibit a weight-dependent lethal

2 median dose when infected with Methicillin-resistant

3 Staphylococcus aureus

4 Authors

- 5 Poppy J. Hesketh-Best^{1*}, Michelle V. Mouritzen², Kayleigh Shandley-Edwards¹,
- 6 Richard A. Billington¹, and Mathew Upton²
- ¹School of Biological and Marine Sciences, and ²School of Biomedical Sciences,
 University of Plymouth, PL4 8AA UK.
- 9 * Corresponding author: Poppy J. Hesketh Best
- 10 (poppy.heskethbest@plymouth.ac.uk)

11 Abstract

- 12 Galleria mellonella is a recognised model to study antimicrobial efficacy; however,
- 13 standardisation across the scientific field and investigations of methodological
- 14 components are needed. Here we investigate the impact of weight on mortality
- 15 following infection with Methicillin-resistant *Staphylococcus aureus* (MRSA). Larvae
- 16 were separated into six weight groups (180-300 mg at 20 mg intervals) and infected
- 17 with a range of doses of MRSA to determine the 50% lethal dose (LD₅₀), and the
- 18 'lipid weight' of larvae post-infection was quantified. A model of LD₅₀ values
- 19 correlated with weight was developed. The LD₅₀ values, as estimated by our model,
- 20 were further tested *in vivo* to prove our model.
- 21 We establish a weight-dependent LD₅₀ in larvae against MRSA and demonstrate that
- 22 G. mellonella is a stable model within 180-260 mg. We present multiple linear
- 23 models correlating weight with: LD₅₀, lipid weight, and larval length. We demonstrate
- 24 that the lipid weight is reduced as a result of MRSA infection, identifying a potentially
- 25 new measure in which to understand the immune response. Finally, we demonstrate
- that larval length can be a reasonable proxy for weight. Refining the methodologies
- in which to handle and design experiments involving *G. mellonella*, we can improve
- 28 the reliability of this powerful model.

29 Key Words

- 30 Methicillin-resistant Staphylococcus aureus; Galleria mellonella; antibiotic testing;
- 31 LD₅₀; pre-clinical model; fat body

32 Introduction

Galleria mellonella (Greater wax moth) larvae are widely utilised for toxicity 33 34 screening (Desbois and Coote 2012; Maguire, Duggan and Kavanagh 2016; Coates 35 et al. 2019) and to study host-pathogen interactions (Peleg et al. 2009; Olsen et al. 36 2011; Junqueira 2012; Wojda and Taszłow 2013). Unlike many insect models, G. 37 *mellonella* can be incubated at 37°C, which facilitates the investigation of human 38 pathogens. This has included most of the ESKAPE pathogens: Enterococcus 39 faecium (Chibebe Junior et al. 2013; Luther et al. 2014); Staphylococcus aureus 40 (Brackman et al. 2011; Ramarao, Nielsen-Leroux and Lereclus 2012; Sheehan, 41 Dixon and Kavanagh 2019); Klebsiella pneumoniae (Wand et al. 2013; Diago-42 Navarro et al. 2014); Acinetobacter baumannii (Peleg et al. 2009); and 43 Pseudomonas aeruginosa (Jander, Rahme and Ausubel 2000; Seed and Dennis 44 2008). Additionally, Escherichia coli (Leuko and Raivio 2012; Alghoribi et al. 2014; 45 Jønsson et al. 2017; Guerrieri et al. 2019), Bulkholderia mallei (Schell, Lipscomb and 46 DeShazer 2008) and several fungi (Cotter, Doyle and Kavanagh 2000; Reeves et al. 47 2004; Mylonakis et al. 2005) have also been studied using G. mellonella. Crucially, a 48 positive correlation between the virulence and immune responses between 49 mammalian models and G. mellonella has been established for P. aeruginosa (Jander, Rahme and Ausubel 2000), Cryptococcus neoformans (Mylonakis et al. 50 51 2005), and S. aureus (Sheehan, Dixon and Kavanagh 2019), demonstrating the 52 powerful potential of this invertebrate model.

53 Antibiotic efficacy at dosages recommended for human use can be tested in G. 54 mellonella, in addition to their toxicity correlating with toxicity observed in murine 55 models (Ignasiak and Maxwell 2017). This has been shown with both natural and 56 synthetic compounds (Gibreel and Upton 2013; Smitten et al. 2019), opening up the 57 possibility of a rapid and cheap model for the early stages of discovery and 58 development of natural and synthetic products, without the challenges of ethical 59 approval, specialist training and the difficulties of using mice-models in early-stage 60 drug development. Infections caused by antibiotic-resistant S. aureus are of global

61 concern and it is listed as a high priority pathogen for which new antibiotics are

62 urgently needed (The World Health Organisation 2017). Methicillin-resistant S.

63 aureus (MRSA) has been utilised with *G. mellonella* for the study of virulence

64 (Mannala et al. 2018), pathogenicity (Ebner et al. 2016), antimicrobial efficacy of

65 existing antimicrobials (Ba *et al.* 2015; Ferro *et al.* 2016), and for novel candidates

66 (Gibreel and Upton 2013; Jacobs et al. 2013; Dong et al. 2017) (Table S1).

67 Despite the increased popularity of *G. mellonella*, there is much variability in method 68 application (Andrea, Krogfelt and Jenssen 2019). This includes differences in larval size, storage, infective dose, and injection intervals. In this study, we address larval 69 70 size and its potential impact in experimental design. In antibiotic efficacy studies, 71 typically the model is infected with a pathogen shortly before the candidate treatment 72 is presented. This has not been standardised with respect to the parameters 73 previously mentioned for G. mellonella. In our preliminary experimentation in 74 determining a 50% lethal dose (LD₅₀) for MRSA in *G. mellonella*, it was noted that 75 smaller larvae were more susceptible to infection than larger larvae. This was when 76 using a broad range of larval weights (~200-300 mg), as previously reported (Jacobs 77 et al. 2013). Furthermore, the larval weight has been demonstrated to positively 78 correlate with the larval liquid volume, leading to recommendations on how in vivo 79 concentrations of injected compounds and pathogens should be calculated (Andrea, 80 Krogfelt and Jenssen 2019). This led us to hypothesise that the larvae LD_{50} for a 81 pathogen, in our case here MRSA, is directly proportional to the larvae weight and 82 that larvae weight is an essential parameter in experimental design that must be 83 tightly controlled.

84 When physical and anatomical barriers are breached, the wax moth larvae have an 85 innate immune response relying on germline-encoded factors for the detection and 86 clearance of microbial pathogens (Trevijano-Contador and Zaragoza 2019). There 87 are two branches, cellular and humoral immunity. Cellular immunity is conducted by 88 haemocytes, which are present in an open circulatory system called the 89 haemolymph, which is analogous to vertebrate blood. There are at least six 90 subpopulations of haemocytes which perform similar roles to those of the myeloid 91 lineage in vertebrates (Boman and Hultmark 1987; Lavine and Strand 2002), and 92 they are also associated with digestive system, trachea and fat body (Ratcliffe 1985). 93 Five types of haemocytes were identified in fifth larval instar of G. mellonella;

94 prohaemocytes, plasmatocytes, granulocytes, oenocytoids and spherulocytes

- 95 (Salem *et al.* 2014). The main immune processes include coagulation, phagocytosis
- 96 and encapsulation (Tojo *et al.* 2000). Circulating haemocyte density increases during
- 97 pathogenesis due to the release of suspended cells from the fat body (Tojo *et al.*
- 98 2000). Haemocyte density and subpopulation variations changes with time of
- 99 exposure to pathogen and pathogen virulence (Arteaga Blanco et al. 2017).
- 100 Melanisation additionally occurs in the haemolymph, the process of melanin
- 101 production resulting in the darkened appearance of the larvae (Tojo *et al.* 2000). The
- 102 humoral branch is involved in the production of lytic enzymes (Vogel *et al.* 2011),
- and antimicrobial peptides (AMPs) that are active against bacterial pathogens
- 104 (Cytryńska et al. 2007; Tsai, Loh and Proft 2016). These molecules are mostly
- produced by the larval 'fat body', analogous to the mammalian liver, and are
- 106 released into the haemolymph (Zasloff 2002).
- 107 A proteomic investigation has shown *S. aureus* infections lead to an increase in
- 108 production of proteins such as AMPs and peptidoglycan recognition proteins
- 109 (Sheehan, Dixon and Kavanagh 2019). Critically, the same study identified
- similarities between *G. mellonella* and mammal immune response to *S. aureus*
- 111 infections. What has not been investigated is the physiological change in *G*.
- 112 mellonella lipid as a result of S. aureus infections. For this investigation, we were
- 113 motivated to quantify the lipid weight, a proxy for the fat body, of the larvae to
- observe how the fat body might have been affected as a result of MRSA infection.
- 115 The aim of the work here is to investigate methodological adjustments which may
- improve the reproducibility and reliability of using pet-food grade *G. mellonella* as an
- 117 experimental model. This was achieved by (i) examining the effect of larval weight on
- the LD₅₀ to MRSA infection, and (ii) characterising physiological changes occurring
- to lipid weight as a result of the larval immune response to MRSA.
- 120 Materials and Methods
- 121 Cultivation of MRSA
- 122 A single colony of Methicillin-resistant Staphylococcus aureus (MRSA) NTCT 12493
- 123 was streaked onto fresh Luria broth (LB, Fischer Scientific, UK; Tryptone 10 g/L,
- 124 yeast extract 5 g/L, and sodium chloride 10 g/L) solidified with 1.5% agar (Acros

- 125 Organics, UK) 24 h before experimentation. Single colonies were suspended in
- 126 Dulbecco A Phosphate buffered saline (PBS, Oxoid UK) to a range of optical density
- 127 (OD) read at 600 nm (Eppendorf BioPhotometer, Netherlands). These dilutions were
- 128 OD₆₀₀ = 0.1 1.0 in 0.1 increments. Viable cell counts were made of each dilution.
- 129 Determining a weight-based LD₅₀ for Galleria mellonella larvae
- 130 Larvae were purchased commercially from Livefoods UK Ltd. (Somerset, UK;
- 131 www.livefoods.co.uk). On receipt, larvae were individually weighed using an
- accurate scale and grouped into the following weight bands: 180-200, 201-220, 221-
- 133 240, 241-260, 261-280, and 281-300 mg. Larvae were stored at 4°C for up to 7 days
- 134 in the dark with no food and water. Healthy larvae were identified by a uniform cream
- 135 colour, with no indications of melanisation such as spots or markings (Fig. 1A) (Li *et*
- 136 *al.* 2018). Larvae were euthanised by chilling them at 4°C for 1 h, before freezing
- 137 them at -20°C for a minimum of 24 h.




Figure 1: *Galleria mellonella* larvae. (A) Melanisation is a visual indication of the health of the larvae, as larvae progress from none to complete melanisation as a result of stress and/or infection. (B) Larvae pupation. (C) Route of infection for larvae is by intrahaemocoelic injection at the penultimate pro-leg (arrow). Larvae diagram was adapted from Singkum *et al.* (2019). (D) Larvae are divided up into six weight groups.

- 144 Larvae (n = 10) from each weight band were infected by injecting 10 μ l of one of the
- 145 10 dilutions of MRSA into the left penultimate pro-leg (Fig. 1C), using a 50 µl
- 146 Hamilton 750 syringe (Hamilton Company, UK) with a removable needle. Injected
- 147 larvae were placed into Petri dishes lined with tissue paper (KIMTECH, UK). Three

- independent replicates of this experiment were carried out. Syringes were cleaned
 before and after each bacterial dilution. Cleaning consisted of taking up and
 discarding of each wash solution thrice before progressing to the next wash solution.
- 151 Wash solution order was as follows: distilled H_2O (d H_2O), 70% ethanol, and d H_2O .

152 After infection, the larvae were maintained at 37°C in the dark without food or water.

- 153 A placebo control of sterile PBS was used to account for the effect of the physical
- trauma of injection, along with a non-manipulation (NM) control. After 24 h the
 live/dead counts were recorded. Larvae were recorded as dead when they met the
- 156 following: (i) complete melanisation (Fig. 1A), (ii) did not respond to touch, and (iii)
- 157 could not correct itself when rolled onto its back.
- Determining the weight-dependent LD₅₀, live/dead counts were converted into 58 59 percentage mortality at 24 h for each group. For this investigation we have defined LD₅₀ as CFU of MRSA per mg of organism resulting in 50% mortality. To model the 60 61 dose-response and describe the relationship between increasing the infection dose 62 on survival for each weight group, a non-linear sigmoidal regression curve was 63 plotted. The infection dose, represented as CFU/ mg of total weight of larva, was log-64 transformed. A non-linear regression curve was calculated to fit best the data 65 generated from three independent replicas. From the equation generated from this 66 curve, the theoretical LD₅₀ was calculated along with the standard deviation (SD). 67 Estimated LD₅₀ from each weight groups were plotted against the mean larvae weight. A regression line was drawn, and the coefficient of determinant R^2 was 68 69 calculated.
- 170 Correlating larval size with rate of pupation

On the day of receipt, larvae were placed into weight groups in Petri dishes. They
were immediately placed at 37°C, in the dark with no food or water and permitted to

- 173 pupate over 15 days. Larvae were observed daily and pupation events recorded.
- 174 Quantifying lipid weight of G. mellonella

175 Following investigation of the LD₅₀ for MRSA, the lipid weight for all living and dead

176 larvae was quantified. Live larvae from treatments, the NM and PBS controls were

177 ethically euthanised. Dead larvae were stored at -20°C until needed. Larvae were left

to thaw at room temperature for 24 h and were weighed and individually placed in

- 179 Eppendorf tubes to be dried over 7 days at 55°C, and re-weighed to reveal their dry
- 180 weight. Larvae were then submerged in ≥99.9% diethyl ether (Sigma-Aldrich, UK)
- 181 and left for 3 days at 4°C to dissolve lipid. Diethyl ether was utilised as the lipid
- 182 extraction solvent (Tzompa-Sosa *et al.* 2014). After, ether was left to evaporate in a
- 183 fume hood for 24 h. Once dried, larvae were weighed again to acquire the post-ether
- 184 weight. Quantities are then presented as followed: 'total weight' is the weight of the
- 185 larvae pre-experimentation; 'water weight' (*water weight* =
- 186 pre-experimentation weight dry weight); 'lipid weight' (*lipid weight* =
- $187 \quad dry weight post-ether weight).$
- 88 Statistical analysis
- All statistical analysis was performed using PRISM GraphPad 8.4.2 (GraphPad
- 190 Software, San Diego, CA, USA). One-Way ANOVA (two-tailed), Two-Way ANOVA,
- and Pearson's correlation coefficients were used when applicable to compare
- 192 treatment groups. Log-rank Mantel-Cox tests compared survival curves for
- 193 antimicrobial efficacy tests and pupation. A *p*-value of: < 0.05 (*), < 0.01 (**) or <
- 194 0.001 (***), < 0.0001 (****) was considered to be significantly different.
- 195 Results

196 Larval weight affects LD₅₀

197 To begin testing our hypothesis, LD₅₀ values were determined for each weight group. 198 A sigmoidal non-linear model best fit the dose-dependent response of the data, 199 resulting in an LD₅₀ calculated for each weight group (Fig. 2). When adjusted to the 200 number of cells injected into each larvae per one unit of body weight (CFU/mg), the 201 resulting LD₅₀ ranged from 1.19×10^7 CFU/mg, for the 180-200 mg group, to the 202 highest LD₅₀ which was 8.97 x10⁷ CFU/mg for the 261-280 mg group (Table 1). The 203 LD_{50} increased across weight groups except for the 281-300 mg group, which had a 204 lower LD₅₀ than the 261-280 mg weight group. Throughout this experiment, we 205 encountered some difficulties when handling larvae from the two higher weight-206 bands (261-280 and 281-300 mg), such as high variation in mortality at the lowest 207 infective dosages (0-40% mortality) and highest dosages (60-100% mortality). 208 Nevertheless, we were able to calculate an LD₅₀ with the final data.




Figure 2. Sigmoidal non-linear logistic regressions best fit the dose-dependent
 response observed when calculating an LD₅₀ for MRSA. LD₅₀ was calculated for each weight
 group with 10 larvae/group. Data are shown as mean ± SD (n = 10) of three independent
 replicas.

Table 1. Summary of the LD₅₀s as calculated by non-linear models for each weight group (N, number of replicas; R², coefficient of determination).

Weight group	LD_{50}	SD	Ν	R^2
(mg)	(CFU/mg] ^(a)	(CFU/mg)		
180-200	1.19 x10 ⁷	1.47	30	0.85
201-220	1.26 x10 ⁷	2.45	30	0.77
221-240	2.34 x10 ⁷	1.57	30	0.80
241-260	4.40 x10 ⁷	3.35	30	0.76
261-280	8.97 x10 ⁷	1.46	30	0.69
281-300	4.19 x10 ⁷	1.81	30	0.78



210

^(a)Example of how this is calculated can be found in Table S3

- 218
- 219 We observed a positive correlation between weight of the larvae and LD₅₀, as
- 220 calculated by Pearson correlation test (r = 0.87, p = 0.025, n = 18). A linear
- regression model arriving at an equation (y = 0.007966x + 5.548) was used to
- estimate LD₅₀ (Fig. 3A). The LD₅₀ values, as estimated by our model, were tested *in*

- 223 *vivo*, demonstrating an approximate 50-56% (± 5.7 10%) survival for four of the
- weight groups (Fig. 3B). Survival at 24 h for the weight groups 261-280 and 281-300 mg was $30\% (\pm 0\%)$ and $43\% (\pm 15.3\%)$, respectively.




Figure 3. LD₅₀ as calculated by non-linear regression models positively correlated with weight and was validated *in vivo* for all but the two highest weight groups. (A) Calculated LD₅₀ by non-linear models correlation positively with total weight. (B) LD₅₀ value as calculated by the model was validated by injecting into larvae and observing mortality. Data are shown as mean ± SD (n=10) of three independent replicas.

232 MRSA infection leads to a reduction in lipid weight

- With the non-manipulated (NM) group, we assessed the overall relationship between total weight, dry weight, and lipid weight and length of the larvae (Fig. 4). Determined by Pearson's correlation test, we found a positive correlation between the total and dry weight, (r = 0.972, p < 0.0001, n = 83) (Fig. 4A), and total and water weight (r =
- 237 0.989, p < 0.0001, n = 83) (Fig. 4B). These two results support the findings of
- 238 previous research (Andrea, Krogfelt and Jenssen 2019). Two additional positive
- correlations were observed between total weight and lipid (r = 0.788, p < 0.0001, n =
- 240 83) (Fig. 4C), and total weight and length (r = 0.9944, p < 0.0001, n = 252) (Fig. 4D).







Figure 4. Multiple correlations observed between larvae total weight and dry weight, water weight, lipid weight, and larvae length. Non-manipulated (NM) larvae were used to analyse the relationships between (A) total weight and dry weight, (B) total weight and the lipid weight after here presented as lipid weight, (C) total weight and lipid weight as proportional to the total weight, water weight, and (D) total weight and larvae length where data is presented as mean ± SD (n = 252).


- 248 We also investigated the effect of infection on the lipid weight of all the larvae used in
- 249 determining the LD₅₀ for MRSA (Fig. 5). As calculated by one-way ANOVA, injection
- with MRSA resulted in an overall decrease in the lipid weight for both dead (18.7 mg
- \pm 8.541, p < 0.0001, n = 573) and live larvae (22.4 mg ± 6.556, p < 0.0001, n = 524),
- when compared to the NM control (31.92 mg \pm 8.815, n = 83) (Fig 5A). When
- 253 compared to one another, live larvae had a significantly greater lipid weight
- compared to dead larvae (p < 0.0001). There was no significant reduction in the lipid
- 255 weight between NM and PBS control (27.81 mg \pm 5.825, *p* > 0.999, n = 50) (Fig 5A
- and Table S2).



259 Figure 5. Injection of the larvae with MRSA results in an overall decreased in the lipid weight 260 of the larvae. (A) Statistical results from a one-way ANOVA are illustrated above the bars as 261 compared to the NM control. Summary of multiple analysis can be found in Table S2. (B) 262 Box-plots above and to the right of the scatter plot are to illustrate the distribution of the data. 263 Colours are as follows: black, NM control; purple, PBS control; blue, live larvae; and red, dead larvae 24 h post-MRSA infection. Correlations of infective dose and lipid weight for (C) 264 265 living and (D) dead larvae. Data is presented as Log[CFU], as the infective doses are not 266 adjusted for larvae weight. Data presented as mean \pm SD (n = 10) of three independent 267 replicas.

- 268 Finally, we observed that at a high infective dosage of MRSA, the larvae had a lipid
- 269 weight close to the mean of the NM and PBS control compared to the lower dosages
- 270 (Fig. 5C-D). This was supported by a positive correlation between lipid weight and
- infective dose for both live (r = 0.778, p = 0.008) (Fig. 5C) and dead larvae (r =
- 272 0.669, *p* = 0.035) (Fig. 5D).
- 273 Pupation is unaffected by weight

To explore whether larger larvae were closer to the final instar stage (pupae) in which they begin to pupate into adult moths, an observational experiment was performed. NM larvae were left to pupate at 37°C, and it was observed that 80-100% of larvae pupated within the 15 day incubation period, independent on their weight grouping, as calculated by Log-rank (Mantel-Cox) test ($X^2(5, N = 60) = 4.004, p =$ 0.549) (Fig. 6).



280

281Figure 6. The weight did not influence the probability of pupation of NM larvae. NM larvae282were incubated at 37°C for 15 days and observed daily for pupation events. No significant283difference was found between the weight group and the probability of pupation as calculated284by a Log-rank Mantel-Cox test (p = 0.5489). Data are shown as mean \pm SD (n = 10)285repeated twice.

286 Discussion

287 MRSA exhibits a weight-dependent LD₅₀

In this study, we have demonstrated it is possible to develop a model in which a LD₅₀

- can be predicted based on the weight of the larvae, and that the prediction can be
- experimentally validated (Fig. 3). The linear model correlating total and water weight
- 291 (Fig. 4B) imply that in increasingly larger larvae, the *in vivo* dilution of MRSA
- increases requiring a greater density of pathogen to reach the LD₅₀. Likewise for the

- 293 positive correlation confirmed with total and lipid weight (Fig. 4C), the presence of a 294 larger fat body that can be degraded for the production of immune factors, may well 295 be why we observe the weight-dependent effect on LD_{50} . The LD_{50} s (1.19 – 8.97) 296 $x10^7$ CFU/mg) for the MRSA strain was not within range of infective dosages utilised 297 in previously investigated MRSA and Methicillin-sensitive S. aureus (MSSA) strains 298 $(0.8 - 5.0 \times 10^6 \text{ CFU})$ (Table S1). However, a direct comparison may not be 299 appropriate given the variation in reporting densities as in our study the LD₅₀ was 300 adjusted to account for in vivo dilution in the larvae as described in Andrea, Krogfelt
- and Jenssen (2019), but this is not always done.
- 302 During the process of this investigation, we found two of the largest weight groups 303 (261-280 and 281-300 mg) to be unreliable, which hindered progress. This was 304 consistent across multiple batches of larvae orders. LD₅₀, as calculated by our model 305 for 261-280 and 281-300 mg larvae, resulted in less than 50% survival at 24 h (Fig. 306 3B), indicating that our model for a weight-dependent LD_{50} had overestimated the 307 LD₅₀. Our first assumptions were that larger larvae were older and closer to pupation 308 than the smaller weight groups, as larvae increase in size until pupation (Jorjão et al. 309 2018), which might somehow impact on survival. Given the difficulty in identifying an age for each larva, it is a difficult hypothesis to test beyond quantifying the number of 310 311 days it took for NM larvae from each weight group to pupate.
- 312 When this was conducted, we found that larval size did not influence the probability 313 of pupation (Fig. 6), and we conclude that the larvae received from the supplier had 314 an 80-100% probability of pupating within 15 days if kept at 37°C, regardless of 315 weight. It would appear that larger larvae were not likely to be closer to pupation than 316 smaller ones, so the reason for our observed decrease in LD₅₀ for large larvae 317 remains unknown. Since larvae were kept without food, this may be a reason for the 318 observed similar pupation times across all weight groups as lack of food source may 319 be forcing the larvae into pupation. Feeding regimes are not the standard protocol 320 when investing antibiotic efficacy, as such we feel this best represented the 321 conditions larvae would be exposed to at the start of experimentation. 322 Using G. mellonella does have drawbacks, one such being the functional equivalent
- of adaptive immunity termed 'immune priming' (Little and Kraaijeveld 2004; Sadd
 and Schmid-Hempel 2006). Individual larvae that survive infection or exposure to a

325 particular pathogen may exhibit increased immune resistance against the same or 326 similar pathogens. Priming with heat-killed pathogens was observed to result in 327 increased larval survival (Wu et al. 2014). Ultimately there will be no control over the 328 immune history of the larvae and this should always be recognised when working 329 with pet-food grade G. mellonella. Across the literature, a wide range of weight 330 bands have been utilised: 150-200 mg (Mannala et al. 2018); 300-700 mg (Ebner et 331 al. 2016); 200-300 mg (Jacobs et al. 2013); and in other studies this is not declared 332 (Ba et al. 2015; Jorjão et al. 2018). Our results suggest that choosing weight ranges 333 as wide as 300-700 mg and 200-300 mg could result in inconsistent data. While a 334 weight range of only 20 mg is likely a conservative approach, ranges such as 100 335 mg or greater in our weight-dependent LD₅₀ model for MRSA indicates that there 336 would be significant differences in survival (Fig. 3A).

337 Weighing individual larvae is a time-consuming procedure. This study also 338 demonstrated that larvae length is reasonable proxy for the weight (Fig. 4D). Larval 339 length has been previously used to characterise larvae for experimentation where 340 larvae of 15-25 mm were utilised (Bazaid et al. 2018). Like total weight, a large 341 length grouping may also encounter similar challenges. A 20 mg weight grouping 342 would equate to roughly 1 mm, for example, 180-200 mg would be 20-21 mm. 343 Measuring length may be a preferred alternative to accurately weighing all larval. 344 When sourcing larvae from our supplier, we frequently found that larvae belonging to 345 the weight groups 201-220 and 221-240 mg were most abundant, which will 346 inevitably be the practical determining factor in weight group selection. Our findings 347 would support selection of larvae in this range.

348 Lipid metabolism occurs in response to MRSA infection

349 MRSA infection leads to a decreased lipid weight in the larvae after 24 h, whether 350 they died or survived the infection (Fig. 5A). The reduction in lipid weight is likely the 351 result of lipolysis during an immune response. This is to be expected, the fat body of 352 the larvae produce many defence compounds essential to the larvae's immune 353 response (Cytryńska et al. 2007; Tsai, Loh and Proft 2016). This reaction can be 354 rapid, in some models showing production of AMPs within the first 4 to 6 h post-355 infection (Sheehan, Dixon and Kavanagh 2019; Trevijano-Contador and Zaragoza 356 2019). This is supported by proteomic work, which demonstrated that at 6 and 24 h

post-*S. aureus* infection larvae had increased expression of AMPs (Sheehan, Dixonand Kavanagh 2019).

359 On exposure to the infecting pathogen, there may be a rapid metabolism of the fat 360 body to provide the required energy to fight the infection. Larvae with larger lipid 361 weight before infection might be more likely to survive, as seen with the surviving 362 larvae having a greater lipid weight than dead larvae (Fig. 5A). Within this 363 experimental design, the larvae are not fed before or during the experiment, and 364 therefore they cannot be acquiring more lipid. Where lipid weight was seen as closer 365 to the NM and PBS control baseline, as observed in the trend of lipid weight 366 positively correlating with infective dose (Fig. 5C-D), it is more likely that lipid 367 metabolism has been compromised.

What could reasonably be expected is that lipolysis of the fat body occurs to
increase the production of AMPs and additional defence compounds. When *Drosophila* are stimulated by a systemic infection with *S. aureus*, signalling from the
Toll receptor increases, which leads to increased production of AMPs and reduced
accumulation of lipids (Liu *et al.* 2016; Lee and Lee 2018). This could suggest that
for larvae surviving high infective dosages, there are additional immune responses
that do not deplete the fat body.

We intended to quantify the larval lipid weight to aid in understanding the weightdependent LD₅₀ effect and the observed unreliability of the two largest weight groups (261-280 and 281-300 mg). We report several observations regarding the lipid weight and MRSA infection; however, none can fully explain the irregularity we encountered for the largest weight groups. Analysing larval lipid weight has proved some insight, but would benefit from further investigation, though alternative methods to estimate lipid mass would be required.

382 Overall assessment of G. mellonella as a model

383 There remains a lack of widely available and cheap standardised stocks of larvae

reared under controlled conditions. Temperature (Mowlds and Kavanagh 2008), diet

385 (Banville, Browne and Kavanagh 2012; Jorjão *et al.* 2018), past infections (Fallon,

386 Kelly and Kavanagh 2012), and antibiotics and hormones in the feed (Büyükgüzel

and Kalender 2008) are all reported to influence laboratory experimentation. Most

larvae currently used are acquired from commercial insect food providers (Andrea,
Krogfelt and Jenssen 2019), where it is understood that use of antibiotics and
hormones in the culture medium is common practice, and acquiring accurate
information regarding the conditions in which the larvae are reared is challenging. All
of which may vary between larvae suppliers, which is a challenge that warrants
further investigation.

394 Ultimately from our investigation, it would appear that lipid deposits are essential in 395 G. mellonella response to MRSA. Prior investigation has evaluated the effect of 396 nutrient deprivation on larvae (Banville, Browne and Kavanagh 2012), and the 397 selection of diet (Jorjão et al. 2018), which both influence susceptibility to S. aureus 398 infection. This emphasises the issues associated with a having lack of knowledge of 399 rearing conditions used by suppliers and how they will influence experimental 400 results. TruLarv[™] (BioSystems Technology, UK) currently provide the only 401 standardised G. mellonella in the UK. While cheap compared to murine models, it is 402 considerably costlier (£1.20 per larvae) than purchasing larvae from commercial pet 403 food providers.

404 However for pet-food grade larvae to be reliably used in research, more significant 405 consideration should be taken over the parameters that can be controlled, and in this 406 study, we emphasise that such experiments can be reproducible and reliable. We 407 recommend that investigators consider the potential variability associated with using 408 different larval weight as we have shown herein. We would recommend using weight 409 groupings as a means to control this. . Our data suggests that all larvae used should 410 be within 10 mg of the mean weight of all larvae to provide consistency. Additionally, 411 larvae of >260 mg should not be avoided.

412 In this work, we present several linear regression curves that could be used as tools 413 to aid in experimental design, such as the linear model for LD_{50} (Fig. 3A), weight and 414 lipid content (Fig. 4C), and length (Fig. 4D). Finally, we demonstrate that the lipid 415 weight is reduced as a result of MRSA infection, identifying a potentially new 416 measure in which to understand the immune response. Similarities between G. 417 mellonella and mammals in response to S. aureus infections can be used to study 418 the efficacy and interactions of novel antimicrobials, even at early development stages. By refining and standardising methodologies in which to handle and select 419

- 420 *G. mellonella* for study, we can improve the reliability of this powerful model for
- 421 multiple purposes.

422 Author Contributions

- 423 Conceptualisation, PJHB and MVM; Methodology, PJHB, MVM, KSE, RAB, and MU;
- 424 Validation, PJHB, MVM, and KSE; Formal Analysis, PJHB; Investigation, PJHB and
- 425 MVM; Resources, PJHB and MVM; Data Curation, PJHB and MVM; Writing –
- 426 Original Draft Preparation, PJHB; Writing Review & Editing, PHB, MVM, KSE,
- 427 RAB, and MU; Visualization, PJHB; Supervision, RAB, and MU; Funding Acquisition,428 MU.

429 Funding

- 430 This study was funded in part by the University of Plymouth, School of Biology and
- 431 Marine Science postgraduate research studentship and Innovate UK Antibiotic
- 432 Development grant (Innovate UK 103358).

433 **Transparency declaration**

- The authors declare no conflict of interests. The funders had no role in the design of
- 435 the study; in the collection, analyses, or interpretation of data; in the writing of the
- 436 manuscript, or in the decision to publish the results.

437 **References**

- 438 Alghoribi MF, Gibreel TM, Dodgson AR *et al. Galleria mellonella* infection model
- demonstrates high lethality of ST69 and ST127 uropathogenic *E. coli. PLoS One* 2014;**9**:e101547–e101547.
- 441 Andrea A, Krogfelt KA, Jenssen H. Methods and Challenges of Using the Greater
- 442 Wax Moth (*Galleria mellonella*) as a Model Organism in Antimicrobial
- 443 Compound Discovery. *Microorganisms* 2019;**7**:85.
- 444 Arteaga Blanco LA, Crispim JS, Fernandes KM *et al.* Differential cellular immune
 445 response of *Galleria mellonella* to *Actinobacillus pleuropneumoniae*. *Cell Tissue*446 *Res* 2017;**370**:153–68.
- 447 Ba X, Harrison EM, Lovering AL et al. Old drugs to treat resistant bugs: Methicillin-
- 448 resistant *Staphylococcus aureus* isolates with mecC are susceptible to a
- 449 combination of penicillin and clavulanic acid. *Antimicrob Agents Chemother*

- 450 2015;**59**:7396–404.
- 451 Banville N, Browne N, Kavanagh K. Effect of nutrient deprivation on the susceptibility
 452 of *Galleria mellonella* larvae to infection. *Virulence* 2012;**3**:497.
- 453 Bazaid AS, Forbes S, Humphreys GJ et al. Fatty Acid Supplementation Reverses
- 454 the Small Colony Variant Phenotype in Triclosan-Adapted *Staphylococcus*
- 455 *aureus*: Genetic, Proteomic and Phenotypic Analyses. *Sci Rep* 2018;**8**, DOI:
- 456 10.1038/s41598-018-21925-6.
- 457 Boman HG, Hultmark D. Cell-free immunity in insects. *Annu Rev Microbiol*458 1987;**41**:103–26.
- 459 Brackman G, Cos P, Maes L *et al.* Quorum sensing inhibitors increase the
- 460 susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. *Antimicrob*461 *Agents Chemother* 2011;**55**:2655–61.
- Büyükgüzel E, Kalender Y. *Galleria mellonella* (L.) Survivorship, Development and
 Protein Content in Response to Dietary Antibiotics. *J Entomol Sci* 2008;**43**:27–
 464 40.
- Chibebe Junior J, Fuchs BB, Sabino CP *et al.* Photodynamic and Antibiotic Therapy
 Impair the Pathogenesis of *Enterococcus faecium* in a Whole Animal Insect
 Model. *PLoS One* 2013;**8**:55926.
- 468 Coates CJ, Lim J, Harman K *et al.* The insect, *Galleria mellonella*, is a compatible
 469 model for evaluating the toxicology of okadaic acid. *Cell Biol Toxicol*470 2019;**35**:219–32.
- 471 Cotter G, Doyle S, Kavanagh K. Development of an insect model for the in vivo
 472 pathogenicity testing of yeasts. *FEMS Immunol Med Microbiol* 2000;**27**:163–9.
- 473 Cytryńska M, Mak P, Zdybicka-Barabas A *et al.* Purification and characterization of
 474 eight peptides from *Galleria mellonella* immune hemolymph. *Peptides*
- 475 2007;**28**:533–46.
- 476 Desbois AP, Coote PJ. Chapter 2 Utility of Greater Wax Moth Larva (*Galleria*
- 477 *mellonella*) for Evaluating the Toxicity and Efficacy of New Antimicrobial Agents.
- 478 In: Laskin AI, Sariaslani S, Gadd GM (eds.). *Advances in Applied Microbiology*.
- 479 Vol 78. Academic Press, 2012, 25–53.

- 480 Diago-Navarro E, Chen L, Passet V *et al.* Carbapenem-resistant *Klebsiella*481 *pneumoniae* exhibit variability in capsular polysaccharide and capsule
 482 associated virulence traits. *J Infect Dis* 2014;**210**:803–13.
- 483 Dong CL, Li LX, Cui ZH *et al.* Synergistic effect of pleuromutilins with other
- 484 antimicrobial agents against *Staphylococcus aureus* in vitro and in an
- 485 experimental *Galleria mellonella* model. *Front Pharmacol* 2017;**8**:553.
- 486 Ebner P, Rinker J, Nguyen MT *et al.* Excreted cytoplasmic proteins contribute to
 487 pathogenicity in *Staphylococcus aureus*. *Infect Immun* 2016;**84**:1672–81.
- Fallon J, Kelly J, Kavanagh K. *Galleria mellonella* as a Model for Fungal
 Pathogenicity Testing. *Methods Mol Biol* 2012;**845**:469–85.
- 490 Ferro TAF, Araújo JMM, dos Santos Pinto BL *et al.* Cinnamaldehyde Inhibits
- 491 Staphylococcus aureus Virulence Factors and Protects against Infection in a
 492 Galleria mellonella Model. Front Microbiol 2016;7:2052.
- Gibreel TM, Upton M. Synthetic epidermicin NI01 can protect *Galleria mellonella*larvae from infection with *Staphylococcus aureus*. *J Antimicrob Chemother*2013;**68**:2269–73.
- 496 Guerrieri CG, Pereira MF, Galdino ACM et al. Typical and Atypical
- 497 Enteroaggregative *Escherichia coli* Are Both Virulent in the *Galleria mellonella*
- 498 Model. *Front Microbiol* 2019;**10**:1791.
- Ignasiak K, Maxwell A. *Galleria mellonella* (greater wax moth) larvae as a model for
 antibiotic susceptibility testing and acute toxicity trials. *BMC Res Notes* 2017;**10**,
 DOI: 10.1186/s13104-017-2757-8.
- 502 Jacobs AC, DiDone L, Jobson J et al. Adenylate kinase release as a high-
- 503throughput-screening-compatible reporter of bacterial lysis for identification of504antibacterial agents. Antimicrob Agents Chemother 2013;57:26–36.
- Jander G, Rahme LG, Ausubel FM. Positive correlation between virulence of *Pseudomonas aeruginosa* mutants in mice and insects. *J Bacteriol*2000;**182**:3843–5.
- 508Jønsson R, Struve C, Jenssen H *et al.* The wax moth *Galleria mellonella* as a novel509model system to study Enteroaggregative *Escherichia coli* pathogenesis.

- 510 *Virulence* 2017;**8**:1894–9.
- Jorjão AL, Oliveira LD, Scorzoni L *et al.* From moths to caterpillars: Ideal conditions
 for *Galleria mellonella* rearing for in vivo microbiological studies. *Virulence*2018;**9**:383–9.
- 514 Junqueira JC. *Galleria mellonella* as a model host for human pathogens: Recent 515 studies and new perspectives. *Virulence* 2012;**3**, DOI: 10.4161/viru.22493.
- 516 Lavine MD, Strand MR. Insect hemocytes and their role in immunity. *Insect* 517 *Biochemistry and Molecular Biology*. Vol 32. Pergamon, 2002, 1295–309.
- 518 Lee KA, Lee WJ. Immune–metabolic interactions during systemic and enteric 519 infection in *Drosophila*. *Curr Opin Insect Sci* 2018;**29**:21–6.
- Leuko S, Raivio TL. Mutations that impact the enteropathogenic *Escherichia coli* Cpx
 envelope stress response attenuate virulence in </i> *Infect Immun* 2012;**80**:3077–85.
- Li Y, Spiropoulos J, Cooley W *et al.* Galleria mellonella a novel infection model for
 the *Mycobacterium tuberculosis* complex. *Virulence* 2018;**9**:1126–37.
- 525 Little TJ, Kraaijeveld AR. Ecological and evolutionary implications of immunological 526 priming in invertebrates. *Trends Ecol Evol* 2004;**19**:58–60.
- Liu B, Zheng Y, Yin F *et al.* Toll Receptor-Mediated Hippo Signaling Controls Innate
 Immunity in *Drosophila*. *Cell* 2016;**164**:406–19.
- 529 Luther MK, Arvanitis M, Mylonakis E *et al.* Activity of daptomycin or linezolid in
- 530 combination with rifampin or gentamicin against biofilm-forming *Enterococcus*
- 531 *faecalis* or *E. faecium* in an in vitro pharmacodynamic model using simulated
- 532 endocardial vegetations and an *in vivo* sur. *Antimicrob Agents Chemother*
- 533 2014;**58**:4612–20.
- Maguire R, Duggan O, Kavanagh K. Evaluation of *Galleria mellonella* larvae as an in
 vivo model for assessing the relative toxicity of food preservative agents. *Cell Biol Toxicol* 2016;**32**:209–16.
- 537 Mannala GK, Koettnitz J, Mohamed W *et al.* Whole-genome comparison of high and
 538 low virulent *Staphylococcus aureus* isolates inducing implant-associated bone

539 infections. *Int J Med Microbiol* 2018;**308**:505–13.

- Mowlds P, Kavanagh K. Effect of pre-incubation temperature on susceptibility of *Galleria mellonella* larvae to infection by *Candida albicans*. *Mycopathologia*2008;**165**:5–12.
- 543 Mylonakis E, Moreno R, El Khoury JB *et al. Galleria mellonella* as a model system to 544 study *Cryptococcus neoformans* pathogenesis. *Infect Immun* 2005;**73**:3842–50.
- 545 Olsen RJ, Ebru Watkins M, Cantu CC *et al.* Virulence of serotype M3 group A
 546 *Streptococcus* strains in wax worms (*Galleria mellonella* larvae). *Virulence*547 2011;**2**:111.
- 548 Peleg AY, Jara S, Monga D *et al. Galleria mellonella* as a model system to study
 549 *Acinetobacter baumannii* pathogenesis and therapeutics. *Antimicrob Agents*550 *Chemother* 2009;**53**:2605–9.
- Ramarao N, Nielsen-Leroux C, Lereclus D. The insect *Galleria mellonella* as a
 powerful infection model to investigate bacterial pathogenesis. *J Vis Exp* 2012,
 DOI: 10.3791/4392.
- Ratcliffe NA. Invertebrate immunity A primer for the non-specialist. *Immunol Lett*1985;**10**:253–70.
- Reeves EP, Messina CGM, Doyle S *et al.* Correlation between gliotoxin production
 and virulence of *Aspergillus fumigatus* in *Galleria mellonella*. *Mycopathologia*2004;**158**:73–9.
- Sadd BM, Schmid-Hempel P. Insect Immunity Shows Specificity in Protection upon
 Secondary Pathogen Exposure. *Curr Biol* 2006;**16**:1206–10.
- Salem HM, Hussein MA, Hafez SE *et al.* Ultrastructure changes in the haemocytes
 of *Galleria mellonella* larvae treated with gamma irradiated *Steinernema carpocapsae* BA2. *J Radiat Res Appl Sci* 2014;**7**:74–9.
- Schell MA, Lipscomb L, DeShazer D. Comparative genomics and an insect model
 rapidly identify novel virulence genes of *Burkholderia mallei*. *J Bacteriol*2008;**190**:2306–13.
- 567 Seed KD, Dennis JJ. Development of *Galleria mellonella* as an alternative infection

- 568 model for the *Burkholderia cepacia* complex. *Infect Immun* 2008;**76**:1267–75.
- Sheehan G, Dixon A, Kavanagh K. Utilization of *Galleria mellonella* larvae to
 characterize the development of *Staphylococcus aureus* infection. *Microbiol*(*United Kingdom*) 2019;**165**:863–75.
- 572 Singkum P, Suwanmanee S, Pumeesat P *et al.* A powerful in vivo alternative model
 573 in scientific research: *Galleria mellonella*. *Acta Microbiol Immunol Hung*574 2019;**66**:31–55.
- 575 Smitten KL, Southam HM, de la Serna JB *et al.* Using Nanoscopy To Probe the
 576 Biological Activity of Antimicrobial Leads That Display Potent Activity against
 577 Pathogenic, Multidrug Resistant, Gram-Negative Bacteria. *ACS Nano*578 2019;**13**:5133–46.
- 579 The World Health Organisation. *Global Priority List of Antibiotic-Resistant Bacteria to* 580 *Guide Research, Discovery, and Development of New Antibiotics.*, 2017.
- Tojo S, Naganuma F, Arakawa K *et al.* Involvement of both granular cells and
 plasmatocytes in phagocytic reactions in the greater wax moth, *Galleria mellonella*. *J Insect Physiol* 2000;**46**:1129–35.
- 584 Trevijano-Contador N, Zaragoza O. Immune response of *Galleria mellonella* against 585 human fungal pathogens. *J Fungi* 2019;**5**, DOI: 10.3390/jof5010003.
- 586 Tsai CJ-YY, Loh JMS, Proft T. *Galleria mellonella* infection models for the study of 587 bacterial diseases and for antimicrobial drug testing. *Virulence* 2016;**7**:214–29.
- Tzompa-Sosa DA, Yi L, van Valenberg HJF *et al.* Insect lipid profile: Aqueous versus
 organic solvent-based extraction methods. *Food Res Int* 2014;**62**:1087–94.
- 590 Vogel H, Altincicek B, Glöckner G et al. A comprehensive transcriptome and
- 591 immune-gene repertoire of the lepidopteran model host *Galleria mellonella*.
- 592 *BMC Genomics* 2011;**12**, DOI: 10.1186/1471-2164-12-308.
- Wand ME, McCowen JWI, Nugent PG *et al.* Complex interactions of *Klebsiella pneumoniae* with the host immune system in a *Galleria mellonella* infection
 model. *J Med Microbiol* 2013:**62**:1790–8.
- 596 Wojda I, Taszłow P. Heat shock affects host-pathogen interaction in *Galleria*

- 597 *mellonella* infected with *Bacillus thuringiensis*. *J Insect Physiol* 2013;**59**:894–
 598 905.
- 599 Wu G, Zhao Z, Liu C *et al.* Priming *Galleria mellonella* (Lepidoptera: Pyralidae)
- 600 Larvae With Heat-Killed Bacterial Cells Induced an Enhanced Immune
- 601 Protection Against *Photorhabdus luminescens* TT01 and the Role of Innate
- 602 Immunity in the Process. *J Econ Entomol* 2014;**107**:559–69.
- 603 Zasloff M. Antimicrobial peptides of multicellular organisms. *Nature* 2002;**415**:389–
 604 95.

Supplementary

 Table S1. Summary of experimental design utilised for *G. mellonella* experiments. Table adapted from Andrea, Krogfelt and Jenssen (2019) to include details of strains and a brief summary of their characteristics. (LP, left pro-leg; NA, not available, P-, privately purchased larvae from country specified).

S. aureus strain	Strain characteristics	Larval weight/size	Larval origin	Storage	Injection site	Infection	Reference
EDCC 5455- 5461	clinical isolates	150–200 mg	Reared	30°C	Not given	1.0 x10 ⁶	(Mannala <i>et al.</i> 2018)
EDCC 5464	clinical isolate, MRSA strain						,
RN4220		NA	P-UK	4°C	Between	~1.3 x10 ⁶	(Ba <i>et al.</i> 2015)
LGA251	veterinary isolate, <i>mecC</i> positive				segments		
02.5099.D	clinical isolate, <i>mec</i> C positive						
ATCC 43300	MRSA, type culture	15–25 mm long	P-UK	7 days	LP	0.8–2.6 x10 ⁶	(Bazaid <i>et al.</i> 2018)
Newman							
NCTC 13277	MRSA, type culture						
2x clin. isol.							
ATCC 29213	MSSA	~250 mg	P-China	NA	LP	~1.0 x10 ⁶	(Dong <i>et al.</i> 2017)
ATCC 43300	MRSA						
N54	MSSA, clinical isolate						
MRSA N9	MRSA, clinical isolate						
USA300 JE2	MRSA	300–700 mg	P- Netherlands	NA	LP	1.0 x10 ⁶	(Ebner <i>et al.</i> 2016)
ATCC 25923	type culture	~200 mg	NA	NA	LP	1.0 x10 ³	(Ferro <i>et al.</i> 2016)
ATCC 6538	type culture						
SA01-04	clinical isolates						
USA300-0114		200–300 mg	P-USA	4°C, 14 days	LP	5.0 x10 ⁶	(Jacobs <i>et al.</i> 2013)
UAMS-1		-					
UAMS-1112]					
RN4220]					
ATCC 6538	type culture	NA	Reared	28°C	NA	10 ⁸ CFU/ml	(Jorjão et al. 2018)
ATCC 11195	MSSA, type culture	NA	P-UK	4°C, 14 days	NS	~2.5 x10 ⁶	(Gibreel and Upton 2013)

Table S2. Multiple comparison results for change in lipid weight 24 h post-MRSA infection described in Figure 5. (PBS; phosphate-buffered saline injection; NM, no manipulation control)

Interaction	Mean rank diff.	Adjusted <i>p-v</i> alue	Summary
NM vs. PBS	78.87	>0.9999	ns
NM vs. Live	339.5	<0.0001	****
NM vs. Dead	490.7	<0.0001	****
PBS vs. Live	260.6	<0.0001	****
PBS vs. Dead	411.8	<0.0001	****
Live vs. Dead	151.2	<0.0001	****

Table S3. Editable excel table that can be used in order to calculate the LD50 for MRSA based on weight-grouping.

Calculating the LD50 for MRSA NCTC 12493

Equation as given by linear model: **y = 0.007966x + 5.548**

Larvae weight (mg): x =	180	Insert here the median weight for the selected weight group
LD ₅₀ (Log[CFU/mg]): y =	9.61E+06	This is the LD_{50} for your selected weight group
LD ₅₀ (CFU): 2.88E+09 injected into larva of the se		This is the total density of MRSA 12493 that must be injected into larva of the selected weight-group in order to kill 50% of the population